3 results
Approved WMOCompleted
Primary: To allow continued use of panobinostat to patients receiving single agent therapy with panobinostat in a Novartis-sponsored study.Secondary: To collect long term data on SAEs.
Approved WMOCompleted
Primary* To compare the disease free survival (DFS) in patients with HL after achieving a complete response following AHSCT with HDT who are treated with panobinostat versus those who receive placebo based on investigator*s review of radiological…
Approved WMOCompleted
The primary objectives are to establish dose-response relationship for 2% transdermal testosterone (Tostran®) gel to achieve total testosterone serum concentrations between 1.5-2.5 nmol/l in transgender women after vaginoplasty and to assess side…